|Dr. Stephen J. Hoffman||CEO & Director||776.57k||N/A||1954|
|Dr. Joseph H. Gardner||Founder, Pres & Director||677.57k||N/A||1956|
|Mr. Michael W. Rogers||Chief Financial & Bus. Officer and Principal Financial & Accounting Officer||570.7k||N/A||1960|
|Mr. Kevin G. Peters||Chief Scientific Officer & Acting Chief Medical Officer||N/A||N/A||1957|
|Dr. Dhaval Desai||Chief Strategy Officer||N/A||N/A||1977|
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2b clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Aerpio Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.